Advertisement

A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction

      Abstract

      Objective: Our purpose was to compare the effect of vaginal administration of misoprostol (Cytotec) with that of dinoprostone (Cervidil) on cervical ripening and labor induction. Study design: Two hundred patients with indications for induction of labor and unfavorable cervical examinations were randomly assigned to receive vaginally administered misoprostol (prostaglandin E1) or the dinoprostone (prostaglandin E2) vaginal insert. Twenty-five microgram tablets of misoprostol were placed in the posterior vaginal fornix every 4 hours for a maximum of six doses. Additional misoprostol was not given after either spontaneous rupture of membranes, adequate cervical ripening (Bishop score of ≥8 or cervical dilatation of ≥3 cm), or beginning of active labor. The vaginal insert, Cervidil, containing 10 mg of dinoprostone in a timed-release preparation was placed in the posterior vaginal fornix for a maximum period of 24 hours. The vaginal insert was removed for spontaneous rupture of membranes, entry into active labor, adequate cervical ripening, or abnormality of uterine contractile pattern or fetal cardiac activity. Results: Of the 200 patients enrolled, 99 were randomized to misoprostol and 101 to dinoprostone. The average interval from start of induction to vaginal delivery was 1 hour shorter in the misoprostol group (1296.7 ± 722.1 minutes) than in the dinoprostone group (1360.0 ± 792.0 minutes), but this difference was not statistically significant (p = 0.97). Oxytocin augmentation of labor was used in 50 (50.5%) misoprostol-treated patients and 43 (43.5%) dinoprostone-treated patients (relative risk 1.14, 95% confidence interval 0.86 to 1.51, p = 0.35). There were no significant differences between routes of delivery with misoprostol or dinoprostone. Overall, 38 patients (19.3%) had cesarean deliveries. There was a significantly lower prevalence of tachysystole (six or more uterine contractions in a 10-minute window for two consecutive 10-minute periods) in the misoprostol group (7.1%) than in the dinoprostone group (18.4%) (relative risk 0.52, 95% confidence interval 0.31 to 0.89, p = 0.02). There were no significant differences in frequency of uterine hyperstimulation or hypertonus. Abnormal fetal heart rate tracings were found in 23 (23.2%) of misoprostol-treated patients and 35 (35.7%) of dinoprostone-treated patients (relative risk 0.73, 95% confidence interval 0.52 to 1.01, p = 0.0546). No significant differences were found in meconium passage, 1- or 5-minute Apgar scores <7, neonatal resuscitations, or admissions to the neonatal intensive care unit between the two groups. CONCLUSIONS: Vaginally administered misoprostol is as effective as dinoprostone for cervical ripening and the induction of labor. Mean time intervals to delivery, need for oxytocin augmentation, and routes of delivery were similar between the two groups. Incidence of uterine tachysystole with misoprostol every 4 hours was significantly less than with dinoprostone.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wing DA
        • Jones MM
        • Rahall A
        • Goodwin TM
        • Paul RH.
        A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor induction.
        Am J Obstet Gynecol. 1995; 172: 1804-1810
        • Wing DA
        • Rahall A
        • Jones MM
        • Goodwin TM
        • Paul RH.
        Misoprostol: an effective agent for cervical ripening and labor induction.
        Am J Obstet Gynecol. 1995; 172: 1811-1816
        • Wing DA
        • Paul RH.
        A comparison of differing dosing regimens of vaginally administered misoprostol for cervical ripening and labor induction.
        Am J Obstet Gynecol. 1996; 175: 158-164
        • Sanchez-Ramos L
        • Kaunitz AM
        • Del Valle GO
        • Delke I
        • Schroeder PA
        • Briones DK.
        Labor induction with the prostaglandin E1 methyl analogue misoprostol versus oxytocin: a randomized trial.
        Obstet Gynecol. 1993; 81: 332-336
        • Varaklis K
        • Gumina R
        • Stubblefield PG.
        Randomized controlled trial of vaginal misoprostol and intracervical prostaglandin E2 gel for induction of labor at term.
        Obstet Gynecol. 1995; 86: 541-544
        • Fletcher HM
        • Mitchell S
        • Simeon D
        • Frederick J
        • Brown D.
        Intravaginal misoprostol as a cervical ripening agent.
        Br J Obstet Gynaecol. 1993; 100: 641-644
        • Fletcher HM
        • Mitchell S
        • Frederick J
        • Simeon D
        • Brown D.
        Intravaginal misoprostol versus dinoprostone as cervical ripening and labor-inducing agents.
        Obstet Gynecol. 1994; 83: 244-247
        • Chuck FJ
        • Huffaker BJ.
        Labor induction with intravaginal misoprostol versus intracervical prostaglandin E2 gel (Prepidil gel): randomized comparison.
        Am J Obstet Gynecol. 1995; 173: 1137-1142
        • Bugalho A
        • Bique C
        • Machungo F
        • Bergstrom S.
        A comparative study of vaginal misoprostol and intravenous oxytocin for induction of labor.
        Gynecol Obstet Invest. 1995; 39: 252-256
        • Smith CV
        • Rayburn WF
        • Miller AM.
        Intravaginal prostaglandin E2 for cervical ripening and initiation of labor: comparison of a multidose gel and single, controlled-release pessary.
        J Reprod Med. 1994; 39: 381-386
        • Witter FR
        • Rocco LE
        • Johnson TRB.
        A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term.
        Am J Obstet Gynecol. 1992; 166: 830-834
        • Kubli FW
        • Hon EH
        • Khazin AF
        • Takemura H.
        Observations on heart rate and pH in human fetus during labor.
        Am J Obstet Gynecol. 1969; 104: 1190-1206
        • Stookey RA
        • Sokol RJ
        • Rosen MG.
        Abnormal contraction patterns in patients monitored in labor.
        Obstet Gynecol. 1973; 42: 359-367
        • Meinert CL.
        Clinical trials design, conduct and analysis.
        Oxford University Press, Oxford (UK)1993
        • Witter FR
        • Mercer BM.
        Improved intravaginal controlled-release prostaglandin E2 insert for cervical ripening at term: the Prostaglandin E2 Insert Study Group.
        J Matern Fetal Med. 1996; 5: 64-69